Abstract: Axitinib (AG-013736) is a potent, orally bioavailable, second-generation tyrosine kinase inhibitor (TKI) that selectively targets vascular endothelial growth factor receptors (VEGFR-1, 2, and 3). Originally approved for the treatment of advanced renal cell carcinoma (RCC) following prior systemic therapy failure, its clinical utility is being extensively explored across other malignancies, including hepatocellular carcinoma (HCC), neuroendocrine tumors, and ocular diseases. In the era of precision medicine, research on axitinib has increasingly focused on biomarker discovery to optimize patient selection and monitor therapeutic response. Emerging biomarkers range from clinical indicators, such as treatment-induced hypertension, to molecular and imaging markers, including PD-L1 expression, CD8+ T-cell infiltration, serum proteins (e.g., E-selectin, IL-6), and dynamic contrast-enhanced ultrasound parameters. Furthermore, axitinib's ability to modulate the tumor microenvironment has provided a strong rationale for its combination with immune checkpoint inhibitors (ICIs). This review synthesizes current literature on the pharmacological activity, molecular mechanisms, limitations, and future perspectives of axitinib, with a specific emphasis on its role in biomarker-driven precision medicine.
1. Introduction
Axitinib, also known as AG-013736, is an oral, highly potent, and selective second-generation tyrosine kinase inhibitor (TKI) [1][3]. It was approved by American and European regulatory agencies in 2012 for the treatment of advanced renal cell carcinoma (RCC) after the failure of one prior systemic therapy, such as sunitinib or cytokines [1][2]. Because angiogenesis plays a critical role in tumor growth, duplication, invasion, and metastasis, axitinib's anti-angiogenic properties have made it a subject of intense clinical investigation across various hypervascular solid tumors [1][2]. Beyond RCC, axitinib has demonstrated activity in hepatocellular carcinoma (HCC) [1], neuroendocrine neoplasms (NETs) [4], and is even being evaluated as a suprachoroidal delivery agent for ocular diseases like neovascular age-related macular degeneration [12].
Recently, the oncology landscape has experienced a paradigm shift toward precision medicine and immunotherapy. Axitinib is at the forefront of this transition, serving as a critical combination partner for immune checkpoint inhibitors (ICIs) such as pembrolizumab and avelumab [7][14]. Consequently, current research directions heavily emphasize biomarker discovery to identify patient subpopulations that will derive the maximum benefit from axitinib monotherapy or its immunotherapeutic combinations [14].
2. Pharmacological Activity
Axitinib is administered orally and exhibits rapid absorption, reaching maximum plasma concentrations within four hours of administration [1]. At therapeutic doses, it displays a high protein binding rate exceeding 99%, with a strong preference for albumin [1]. The drug is metabolized predominantly in the liver by the CYP3A4/5 enzymes, and to a lesser extent by CYP1A2, CYP2C19, and UGT1A1, resulting in pharmacologically inactive metabolites [1]. The majority of the drug is excreted via the hepatobiliary route in feces, with less than 20% excreted by the kidneys [1].
Pharmacodynamically, axitinib causes a rapid decrease in blood vessel perfusion and vascular permeability, exhibiting transient pro-apoptotic activity on cancer cells [1]. In preclinical ocular models, axitinib has shown pan-VEGF inhibition that effectively inhibits angiogenic sprouts and regresses established neovascularization, demonstrating superior biocompatibility with retinal pigment epithelial cells compared to other TKIs [12]. Clinically, axitinib significantly improves progression-free survival (PFS) and time to progression (TTP) in advanced RCC and HCC, although it does not always yield a statistically significant overall survival (OS) benefit when used as a monotherapy compared to placebo or active controls like sorafenib [1][3].
3. Molecular Mechanism of Action
Axitinib exerts its primary anti-tumor effects by selectively inhibiting the vascular endothelial growth factor receptors (VEGFR-1, 2, and 3) [1]. By blocking these receptors, it disrupts the VEGF/VEGFR signaling pathway, which is essential for normal vascular development as well as tumor-induced angiogenesis and metastasis [1]. In addition to VEGFRs, axitinib suppresses other receptor tyrosine kinases, including EGFR1/2/3, cKIT, and the platelet-derived growth factor receptor (PDGFR) [1].
In specific cancer models, axitinib modulates several distinct intracellular signaling cascades. In HCC, for instance, axitinib acts as an efficient inhibitor of Klotho-mediated anoikis resistance by suppressing the VEGFR2/PAK1 signaling pathway, thereby preventing anchorage-independent tumor growth [1]. It has also been shown to induce apoptosis in human umbilical vein endothelial cells (HUVECs) and reduce vascular networks via the Akt/mTOR signaling pathway [1].
Crucially, axitinib possesses immunomodulatory activity. Anti-angiogenesis therapy with axitinib can overcome endothelial cell anergy, promote leukocyte-endothelium interactions, and enhance the infiltration of T-cells into the tumor microenvironment [8]. By reversing tumor-induced immune suppression, axitinib primes the tumor microenvironment, providing a robust mechanistic rationale for its synergistic combination with PD-1/PD-L1 checkpoint inhibitors [8][14].
4. Structure-Activity Relationship (SAR)
Axitinib is an indazole derivative synthesized via chemical synthesis, possessing a molecular weight of 386.47 Da [1]. Its specific structural conformation allows it to bind with high affinity to the inactive conformation of the catalytic domain of VEGF receptor tyrosine kinases [1]. This binding mechanism is responsible for its high potency and selectivity as a second-generation TKI compared to first-generation agents. Furthermore, its structural ability to achieve pan-VEGF inhibition (targeting VEGFR-1, 2, and 3) is clinically advantageous; it prevents the compensatory upregulation of alternative VEGF ligands (such as VEGF-C and VEGF-D) that often leads to tachyphylaxis and resistance in therapies targeting only VEGF-A [12].
5. Current Limitations
Despite its efficacy, the clinical utility of axitinib is hindered by several limitations:
Adverse Events (AEs): Axitinib is associated with significant toxicities. Hypertension is a frequent on-target adverse effect, occurring in over 50% of patients in some trials [1]. Other common AEs include diarrhea, fatigue, decreased appetite, hand-foot syndrome (palmar-plantar erythrodysesthesia), proteinuria, and hepatotoxicity (elevated transaminases and hyperbilirubinemia) [1][3]. These toxicities often necessitate dose reductions or treatment discontinuation.
Drug-Drug Interactions: Axitinib can alter the pharmacokinetics of concomitant medications. For example, it noncompetitively inhibits the metabolism of loperamide (a common anti-diarrheal agent), increasing its peak time and decreasing blood clearance. Consequently, concurrent use of axitinib and loperamide should be avoided to prevent toxicity [1].
Therapeutic Resistance: Tumors eventually develop resistance to axitinib. In RCC, chronic TKI use can lead to the upregulation of alternative pathways such as MET and AXL, which bypass VEGFR inhibition [3]. In HCC, the upregulation of the long non-coding RNA LINC00467 has been shown to contribute to axitinib resistance through the miR-509-3p/PDGFRA axis [1].
6. Future Perspectives
The future of axitinib therapy lies in precision medicine, specifically through the discovery of predictive biomarkers and the optimization of combination regimens.
Clinical and Imaging Biomarkers: An increase in diastolic blood pressure (> 90 mm Hg) has been identified as an independent clinical biomarker correlated with longer PFS, OS, and a higher probability of partial response [1]. Imaging techniques, such as dynamic contrast-enhanced ultrasound (DCE-US) measuring tumor fractional blood volume, show promise in monitoring early tumor response to axitinib [1].
Molecular and Serum Biomarkers: In HCC, lower baseline serum levels of E-selectin, stromal cell-derived factor-1, IL-6, and angiopoietin-2 have been associated with significantly longer OS [1]. Additionally, metabolomic profiling has revealed that treatment-related changes—such as increases in 5,6-dihydrouracil and glycopyranose, and decreases in glutamic acid and glutamine—can serve as early indicators of therapeutic response [1].
Immunotherapy Combinations and Gene Signatures: The most significant advancement for axitinib is its combination with ICIs. The FDA has approved axitinib in combination with pembrolizumab (KEYNOTE-426) and avelumab (JAVELIN Renal 101) for the first-line treatment of advanced RCC, as these combinations have demonstrated superior ORR, PFS, and OS compared to sunitinib [7][14]. Biomarker analyses from these trials are actively shaping precision medicine. For instance, the JAVELIN Renal 101 trial identified that tumors positive for PD-L1 or containing higher numbers of CD8+ T-cells at the invasive margin had extended PFS with the axitinib/avelumab combination [14]. Furthermore, gene expression profiling (e.g., assessing angiogenesis vs. immune-effector signatures) is being utilized to predict which patients will benefit most from TKI plus ICI combinations versus ICI monotherapy [14]. Future research will continue to refine these biomarker signatures, utilizing single-cell RNA sequencing and circulating immune cell profiling to durably improve clinical decision-making [14].
